399 related articles for article (PubMed ID: 21435792)
21. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
23. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S; Mazzone M; Hohensinner P; Carmeliet P
Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
[TBL] [Abstract][Full Text] [Related]
24. Targeting angiogenesis with integrative cancer therapies.
Yance DR; Sagar SM
Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711
[TBL] [Abstract][Full Text] [Related]
25. [Neoplasms and angiogenesis].
Lewy-Trenda I
Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
[TBL] [Abstract][Full Text] [Related]
26. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
27. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of resistance to antiangiogenesis therapy.
Azam F; Mehta S; Harris AL
Eur J Cancer; 2010 May; 46(8):1323-32. PubMed ID: 20236818
[TBL] [Abstract][Full Text] [Related]
29. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
30. Response to anti-angiogenesis: an ever changing feature.
Bertolini F
Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
32. [Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Grosicki S; Grosicka A; HoĊowiecki J
Wiad Lek; 2007; 60(1-2):39-46. PubMed ID: 17607967
[TBL] [Abstract][Full Text] [Related]
33. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
Kakeya H; Osada H
Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance to vascular endothelial growth factor blockade.
Abdullah SE; Perez-Soler R
Cancer; 2012 Jul; 118(14):3455-67. PubMed ID: 22086782
[TBL] [Abstract][Full Text] [Related]
36. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
37. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
38. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
39. Angiogenic inhibitors: a new therapeutic strategy in oncology.
Gasparini G; Longo R; Toi M; Ferrara N
Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
[TBL] [Abstract][Full Text] [Related]
40. VEGF targeted therapy in acute myeloid leukemia.
Rodriguez-Ariza A; Lopez-Pedrera C; Aranda E; Barbarroja N
Crit Rev Oncol Hematol; 2011 Nov; 80(2):241-56. PubMed ID: 21035354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]